{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.12","upperLimit":"8.96","value":"1.61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.\n\nmelphalan: Given IV\n\nrecombinant interferon alfa: Given SC\n\naldesleukin: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion\n\nin vitro-treated peripheral blood stem cell transplantation: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion","id":"OG000","title":"Immunotherapy Treatment"}],"paramType":"MEDIAN","populationDescription":"Out of 36 patients, 30 have relapsed and they are used to determine this outcome measure.","reportingStatus":"POSTED","timeFrame":"12.9 years (median)","title":"Time to Disease Progression","type":"PRIMARY","unitOfMeasure":"years"}